粉防已碱抗乳腺肿瘤作用及其机制研究
|
摘要
1目的
乳腺癌是成年女性最常见的恶性肿瘤之一。大约1／3乳腺癌患者呈雌激素受体(ER)阴性,与ER阳性乳腺癌比较,其恶性程度较高,对化疗及内分泌治疗不敏感,预后更差,目前没有理想的治疗方法。ER阴性乳腺癌的治疗是目前临床的难点,因此本研究探讨粉防已碱对ER阴性人乳腺癌MDA-MB-435S细胞作用及其机制,以及对人乳腺癌细胞MCF-7荷瘤裸鼠作用及其机制,以为临床治疗奠定进一步研究的基础。
2方法
2.1体外实验部分
用MTT方法检测粉防已碱7个不同浓度组干预乳腺癌MDA-MB-435S细胞24h、48h、72h、96h后细胞的光吸收值(OD),划细胞生长曲线,并计算各组细胞抑制率及半数抑制浓度(IC50),说明粉防已碱对人乳腺癌MDA-MB-435S细胞体外生长的抑制作用。
碘化丙啶(PI)单染流式细胞术测定法进行粉防已碱4个不同浓度组对人乳腺癌MDA-MB-435S细胞周期分析,观察不同浓度粉防已碱干预24h后各组G0／G1期、G2M期、S期的细胞百分比分布。
利用Annexin V-FITC、PI双标记细胞凋亡检测法检测粉防已碱4个不同浓度组干预人乳腺癌MDA-MB-435S细胞24h、48h后对细胞凋亡的影响。
2.2体内实验部分
建立裸鼠人乳腺癌MCF-7细胞移植瘤动物模型,把24只成瘤动物随机分为模型组、粉防已碱组、阳性对照组,每组8只,共给药15天。治疗期间观察并记录各组裸鼠移植瘤的生长情况及移植瘤体积,药物处理结束后1天,处死裸鼠,称各组裸鼠移植瘤重,并计算抑瘤率。利用光镜及透射电镜观察各组移植瘤组织病理学变化和超微结构变化。利用图像定量分析方法观察各组移植瘤组织的Bcl-2、Bax、Survivin及VEGF蛋白表达水平。
3结果
3.1体外实验部分
粉防已碱7个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组、Tet-6组、Tet-8组、Tet-16组)与同时间点正常对照组(control-1)比较OD值显著降低(P<0.05或0.01),并且随着粉防已碱浓度增加,其OD值降低。同一时间点的药物的抑制率随着粉防已碱浓度的增加而增大,存在量效关系。随着时间的延长,粉防已碱对MDA-MB-435S细胞体外生长的抑制作用增大,存在时间效应。粉防已碱作用于MDA-MB-435S细胞,剂量与时间之间存在交互作用(P<0.01)。24h、48h、72h、96h的IC50值分别为8.748μg/ml,3.585μg/ml、1.451μg/ml、1.117μg/ml。
粉防已碱4个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组)作用于MDA-MB-435S乳腺癌细胞24h后,与同期正常对照组比较,s期、G2M期细胞比例均明显降低,差异具有统计学意义(均P<0.05),并且随粉防已碱浓度增加,S期、G2M期细胞比例降低；G0／G1期细胞比例均显著增高,差异具有统计学意义(均P<0.05),并且随粉防已碱浓度增加,G0／G1期细胞比例增高。
作用24h后粉防已碱4个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组)的早期凋亡率与control-1组比较均增多,差异具有统计学意义(均P<0.05)；48h后与control-1组比较,Tet-1组、Tet-2组、Tet-4组的早期凋亡率显著增多(均P<0.05)；24h、48h早期凋亡率与药物浓度呈正相关(均P<0.05)；并且随作用时间延长,诱导早期凋亡率增加。24h后粉防已碱组晚期凋亡率与control-1组比较无差异(均P>0.05)；随作用时间延长,48h后粉防已碱高浓度组的晚期凋亡率逐渐增多,与control-1组比较差异有统计学意义(均P<0.05)。
3.2体内实验部分
用药第6天以后粉防已碱组和阳性对照组移植瘤体积与同一天的模型组比较显著减小(P<0.05或0.01)；但粉防已碱组和阳性对照组之间无差异(均P>0.05)。粉防已碱组、阳性对照组瘤重比模型组显著降低(P<0.05或0.01)；但粉防已碱组与阳性对照组之间无差异(P>0.05)。粉防已碱组和阳性对照组的抑瘤率分别为25.47%和30.43%。粉防已碱组、阳性对照组移植瘤组织病理学提示腺癌组织中可见坏死及不完全坏死细胞,凋亡现象比模型组增加,凋亡细胞较多。透射电镜观察发现粉防已碱组可见多量凋亡小体形成。
与模型组比较,粉防已碱组和阳性对照组均能降低Bcl-2阳性细胞面积、光密度值和免疫组化指数(P<0.05或0.01)。与模型组比较,粉防已碱组和阳性对照组均能增高Bax阳性细胞面积和免疫组化指数(均P<0.01),粉防已碱组Bax光密度值与模型组比较无差异(P>0.05)。粉防已碱组、阳性对照组Survivin阳性细胞面积和免疫组化指数与模型组比较显著降低(均P<0.01),但粉防已碱组、阳性对照组Survivin光密度值与模型组比较无差异(均P>0.05)。与模型组比较,粉防已碱组和阳性对照组均能降低VEGF阳性细胞面积、光密度值和免疫组化指数(均P<0.01),粉防已碱组和阳性对照组之间比较差异无统计学意义(P>0.05)。
4结论
(1)首次发现粉防已碱对雌激素受体阴性乳腺癌细胞系MDA-MB-435S增殖有明显抑制作用,为临床用于雌激素受体阴性乳腺癌治疗方面提供了基础研究数据。
(2)粉防已碱分别干预MDA-MB-435S细胞24h、48h后可诱导早期凋亡,早期凋亡率与药物浓度呈正相关,且存在浓度和时间依赖性,其最佳浓度范围为0.5μg/ml-4μg／ml。
(3)粉防已碱阻滞MDA-MB-435S细胞于G0／G,期,降低S期比例,抑制DNA合成是其抑制乳腺癌细胞生长的机制之一
(4)粉防已碱对MCF-7裸鼠移植瘤的生长有抑制作用。
(5)粉防已碱抑制MCF-7裸鼠移植瘤生长的作用机制与下调Bcl-2、Survivin、上调Bax蛋白表达而诱导凋亡有关,同时与下调VEGF蛋白表达而抗肿瘤新生血管形成有关。
1 Objective
Breast cancer is one of most common adult female malignant tumors. About 1/3 breast cancer patients show the estrogen receptor(ER) negative, which is insensitive to the chemotherapy and the endocrine therapy. Its malignant degree is higher and prognosis is worse than ER positive breast cancer. At present there are not ideal therapeutic methods. The treatment of ER negative breast cancer is the clinical difficulty. Therefore this research studies the antitumor effect and mechanism of tetrandrine(Tet) on ER negative human breast cancer cell MDA-MB-435S in Vitro and MCF-7 in tumor bearing nude mice,which is to lay the foundation for further studies in clinical treatments.
2 Methods
2.1 Experiments in Vitro
MTT was used to detect optical density (OD) of human breast cancer cell MDA-MB-435S by intervention of Tet in seven different concentration groups in 24h、48h、72h、96h. Drawing cell growth curve,calculating cell inhibitory rate and 50% inhibitory concentration (IC50) in every group, which were used to show inhibitory effect of Tet on human breast cancer cell MDA-MB-435S in Vitro growth.
Propidium iodide (PI) single-staining flow cytometry assay method was used to analyze cell cycles of human breast cancer cell MDA-MB-435S by intervention of Tet in four different concentration groups. To observe cell percentage distribution in G0/G1, G2M, S phases by intervention of different Tet concentration groups after 24h.
Cell apoptosis inspection method of Annexin V-FITC,PI double labelling was used to detect the cell apoptosis effect of Tet on human breast cancer cell MDA-MB-435S in four different concentration groups after 24h and 48h.
2.2 Experiments in Vivo
To build transplanted tumor animal model of human breast cancer cell MCF-7 in nude mice.24 mice with transplanted tumor were randomly divided into model group, Tet group and positive control group,8 mice in each group, administration for 15 days. Detecting and recording the growth condition and volumes of transplanted tumor in every group. Nude mice were killed in the day after administration ending up, weighting the transplanted tumor and calculating tumor inhibitory rate. Light microscope and transmission electron microscopy (TEM) were used to observe histopathologic changes and ultrastructural changes of transplanted tumors in every group. Image quantitative analysis was used to observe Bcl-2, Bax, Survivin and VEGF protein expression level of transplanted tumors in every group.
3 Results
3.1 Experiments in Vitro
As compared with normal control group (control-1) at the same time, OD value was decreased significantly(P< 0.05 or 0.01)in seven different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group, Tet-6 group, Tet-8 group, Tet-16 group),and OD value decreased more significantly as Tet concentration increased. The inhibitory rate of Tet was enlarged with the increase of the concentration in the same time, which exhibited dose-effect relationship. With the passage of time, inhibitory effect of Tet on MDA-MB-435S cell in vitro growth was enlarged, which exhibited time-dependent effect. Interaction effect of dose and time existed for the effect of Tet on MDA-MB-435S cell (P<0.01). IC50 value in 24h,48h,72h,96h were 8.748μg/ml,3.585μg/ml, 1.451μg/ml,1.117μg/ml respectively.
As compared with normal control group in the same phase, cell percentage of S phase, G2M phase in MDA-MB-435S cell were decreased significantly in four different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group) after administration for 24h, with statistical significance (P< 0.05).Higher the Tet concentration, lower the cell percentage of S phase, G2M phase. As compared with normal control group in the same phase, cell percentage of Go/Gi phase were increased significantly, with statistical significance (P < 0.05). Higher the Tet concentration, higher the cell percentage of G0/G1 phase.
As compared with control-1 group after administration for 24h, early apoptosis rate was increased in four different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group),with statistical significance (P< 0.05). As compared with control-1 group after administration for 48h, early apoptosis rate was increased significantly in Tet-1 group, Tet-2 group and Tet-4 group (P< 0.05).Significant positive correlation was observed between early apoptosis rate and Tet concentration after administration for 24h,48h (P<0.05). With the passage of time, early apoptosis rate were increased gradually. There were no difference in late apoptosis rate between Tet groups and control-1 group after administration for 24h(P> 0.05). As compared with control-1 group after administration for 48h, late apoptosis rate were increased gradually in Tet high-concentration groups, with statistical significance (P< 0.05).
3.2 Experiments in Vivo
From 6 days after treatment, volumes of transplanted tumor in Tet group and positive control group were significantly smaller than model group (P<0.05 or 0.01), there were no difference between Tet group and positive control group (P> 0.05).The weight of the transplanted tumor in Tet group and positive control group were significantly decreased than model group (P<0.05 or 0.01) but there were no difference between Tet group and positive control group (P> 0.05). Tumor inhibitory rate in Tet group and positive control group were 25.47% and 30.43% respectively. Transplanted tumor in Tet group and positive control group by hemotoxylin and eosin staining suggested that necrotic cells and incomplete necrotic cells were seen among the adenocarcinoma. More apoptotic cells were found in Tet group and positive control group than model group. It was found by TEM that there were many apoptotic bodies in Tet group.
As compared with model group, the positive cell area, mean optical density and immunohistochemistry index of Bcl-2 in Tet group and positive control group were significantly reduced (P<0.05 or 0.01). As compared with model group, the positive cell area and immunohistochemistry index of Bax in Tet group and positive control group were significantly increased (P<0.01). There were no difference of mean optical density between Tet group and positive control group (P>0.05). As compared with model group, the positive cell area and immunohistochemistry index of Survivin in Tet group and positive control group were significantly reduced (P<0.01). There were no difference of mean optical density among three groups (P>0.05). As compared with model group, the positive cell area, mean optical density and immunohistochemistry index of VEGF in Tet group and positive control group were significantly reduced (P<0.01),but There were no difference between Tet group and positive control group (P> 0.05).
4 Conclusion
(1) It is first found that the effect of Tet on inhibiting ER negative breast cancer MDA-MB-435S cell proliferation is obvious, which provides the basic research data for clinical treatments on ER negative breast cancer.
(2) Tet can induce the early apoptosis after administration for 24h,48h. There is significant positive correlation between early apoptosis rate and Tet concentration.It has concentration and time dependence in the range of 0.5μg /ml to 4μg/ml.
(3)Blocking the cell cycle at G0/G1 phase and reducing the cell percentage of S phase to inhibit the DNA synthesis is one of the antitumor mechanisms of Tet on breast cancer cell in Vitro.
(4)Tet can inhibit the growth of transplanted tumor of MCF-7 in nude mice.
(5)The antitumor mechanisms of Tet on MCF-7 in tumor bearing nude mice are related to reducing Bcl-2, Survivin, VEGF protein expression and increasing Bax protein expression.
乳腺癌是成年女性最常见的恶性肿瘤之一。大约1／3乳腺癌患者呈雌激素受体(ER)阴性,与ER阳性乳腺癌比较,其恶性程度较高,对化疗及内分泌治疗不敏感,预后更差,目前没有理想的治疗方法。ER阴性乳腺癌的治疗是目前临床的难点,因此本研究探讨粉防已碱对ER阴性人乳腺癌MDA-MB-435S细胞作用及其机制,以及对人乳腺癌细胞MCF-7荷瘤裸鼠作用及其机制,以为临床治疗奠定进一步研究的基础。
2方法
2.1体外实验部分
用MTT方法检测粉防已碱7个不同浓度组干预乳腺癌MDA-MB-435S细胞24h、48h、72h、96h后细胞的光吸收值(OD),划细胞生长曲线,并计算各组细胞抑制率及半数抑制浓度(IC50),说明粉防已碱对人乳腺癌MDA-MB-435S细胞体外生长的抑制作用。
碘化丙啶(PI)单染流式细胞术测定法进行粉防已碱4个不同浓度组对人乳腺癌MDA-MB-435S细胞周期分析,观察不同浓度粉防已碱干预24h后各组G0／G1期、G2M期、S期的细胞百分比分布。
利用Annexin V-FITC、PI双标记细胞凋亡检测法检测粉防已碱4个不同浓度组干预人乳腺癌MDA-MB-435S细胞24h、48h后对细胞凋亡的影响。
2.2体内实验部分
建立裸鼠人乳腺癌MCF-7细胞移植瘤动物模型,把24只成瘤动物随机分为模型组、粉防已碱组、阳性对照组,每组8只,共给药15天。治疗期间观察并记录各组裸鼠移植瘤的生长情况及移植瘤体积,药物处理结束后1天,处死裸鼠,称各组裸鼠移植瘤重,并计算抑瘤率。利用光镜及透射电镜观察各组移植瘤组织病理学变化和超微结构变化。利用图像定量分析方法观察各组移植瘤组织的Bcl-2、Bax、Survivin及VEGF蛋白表达水平。
3结果
3.1体外实验部分
粉防已碱7个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组、Tet-6组、Tet-8组、Tet-16组)与同时间点正常对照组(control-1)比较OD值显著降低(P<0.05或0.01),并且随着粉防已碱浓度增加,其OD值降低。同一时间点的药物的抑制率随着粉防已碱浓度的增加而增大,存在量效关系。随着时间的延长,粉防已碱对MDA-MB-435S细胞体外生长的抑制作用增大,存在时间效应。粉防已碱作用于MDA-MB-435S细胞,剂量与时间之间存在交互作用(P<0.01)。24h、48h、72h、96h的IC50值分别为8.748μg/ml,3.585μg/ml、1.451μg/ml、1.117μg/ml。
粉防已碱4个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组)作用于MDA-MB-435S乳腺癌细胞24h后,与同期正常对照组比较,s期、G2M期细胞比例均明显降低,差异具有统计学意义(均P<0.05),并且随粉防已碱浓度增加,S期、G2M期细胞比例降低；G0／G1期细胞比例均显著增高,差异具有统计学意义(均P<0.05),并且随粉防已碱浓度增加,G0／G1期细胞比例增高。
作用24h后粉防已碱4个不同浓度组(Tet-0.5组、Tet-1组、Tet-2组、Tet-4组)的早期凋亡率与control-1组比较均增多,差异具有统计学意义(均P<0.05)；48h后与control-1组比较,Tet-1组、Tet-2组、Tet-4组的早期凋亡率显著增多(均P<0.05)；24h、48h早期凋亡率与药物浓度呈正相关(均P<0.05)；并且随作用时间延长,诱导早期凋亡率增加。24h后粉防已碱组晚期凋亡率与control-1组比较无差异(均P>0.05)；随作用时间延长,48h后粉防已碱高浓度组的晚期凋亡率逐渐增多,与control-1组比较差异有统计学意义(均P<0.05)。
3.2体内实验部分
用药第6天以后粉防已碱组和阳性对照组移植瘤体积与同一天的模型组比较显著减小(P<0.05或0.01)；但粉防已碱组和阳性对照组之间无差异(均P>0.05)。粉防已碱组、阳性对照组瘤重比模型组显著降低(P<0.05或0.01)；但粉防已碱组与阳性对照组之间无差异(P>0.05)。粉防已碱组和阳性对照组的抑瘤率分别为25.47%和30.43%。粉防已碱组、阳性对照组移植瘤组织病理学提示腺癌组织中可见坏死及不完全坏死细胞,凋亡现象比模型组增加,凋亡细胞较多。透射电镜观察发现粉防已碱组可见多量凋亡小体形成。
与模型组比较,粉防已碱组和阳性对照组均能降低Bcl-2阳性细胞面积、光密度值和免疫组化指数(P<0.05或0.01)。与模型组比较,粉防已碱组和阳性对照组均能增高Bax阳性细胞面积和免疫组化指数(均P<0.01),粉防已碱组Bax光密度值与模型组比较无差异(P>0.05)。粉防已碱组、阳性对照组Survivin阳性细胞面积和免疫组化指数与模型组比较显著降低(均P<0.01),但粉防已碱组、阳性对照组Survivin光密度值与模型组比较无差异(均P>0.05)。与模型组比较,粉防已碱组和阳性对照组均能降低VEGF阳性细胞面积、光密度值和免疫组化指数(均P<0.01),粉防已碱组和阳性对照组之间比较差异无统计学意义(P>0.05)。
4结论
(1)首次发现粉防已碱对雌激素受体阴性乳腺癌细胞系MDA-MB-435S增殖有明显抑制作用,为临床用于雌激素受体阴性乳腺癌治疗方面提供了基础研究数据。
(2)粉防已碱分别干预MDA-MB-435S细胞24h、48h后可诱导早期凋亡,早期凋亡率与药物浓度呈正相关,且存在浓度和时间依赖性,其最佳浓度范围为0.5μg/ml-4μg／ml。
(3)粉防已碱阻滞MDA-MB-435S细胞于G0／G,期,降低S期比例,抑制DNA合成是其抑制乳腺癌细胞生长的机制之一
(4)粉防已碱对MCF-7裸鼠移植瘤的生长有抑制作用。
(5)粉防已碱抑制MCF-7裸鼠移植瘤生长的作用机制与下调Bcl-2、Survivin、上调Bax蛋白表达而诱导凋亡有关,同时与下调VEGF蛋白表达而抗肿瘤新生血管形成有关。
1 Objective
Breast cancer is one of most common adult female malignant tumors. About 1/3 breast cancer patients show the estrogen receptor(ER) negative, which is insensitive to the chemotherapy and the endocrine therapy. Its malignant degree is higher and prognosis is worse than ER positive breast cancer. At present there are not ideal therapeutic methods. The treatment of ER negative breast cancer is the clinical difficulty. Therefore this research studies the antitumor effect and mechanism of tetrandrine(Tet) on ER negative human breast cancer cell MDA-MB-435S in Vitro and MCF-7 in tumor bearing nude mice,which is to lay the foundation for further studies in clinical treatments.
2 Methods
2.1 Experiments in Vitro
MTT was used to detect optical density (OD) of human breast cancer cell MDA-MB-435S by intervention of Tet in seven different concentration groups in 24h、48h、72h、96h. Drawing cell growth curve,calculating cell inhibitory rate and 50% inhibitory concentration (IC50) in every group, which were used to show inhibitory effect of Tet on human breast cancer cell MDA-MB-435S in Vitro growth.
Propidium iodide (PI) single-staining flow cytometry assay method was used to analyze cell cycles of human breast cancer cell MDA-MB-435S by intervention of Tet in four different concentration groups. To observe cell percentage distribution in G0/G1, G2M, S phases by intervention of different Tet concentration groups after 24h.
Cell apoptosis inspection method of Annexin V-FITC,PI double labelling was used to detect the cell apoptosis effect of Tet on human breast cancer cell MDA-MB-435S in four different concentration groups after 24h and 48h.
2.2 Experiments in Vivo
To build transplanted tumor animal model of human breast cancer cell MCF-7 in nude mice.24 mice with transplanted tumor were randomly divided into model group, Tet group and positive control group,8 mice in each group, administration for 15 days. Detecting and recording the growth condition and volumes of transplanted tumor in every group. Nude mice were killed in the day after administration ending up, weighting the transplanted tumor and calculating tumor inhibitory rate. Light microscope and transmission electron microscopy (TEM) were used to observe histopathologic changes and ultrastructural changes of transplanted tumors in every group. Image quantitative analysis was used to observe Bcl-2, Bax, Survivin and VEGF protein expression level of transplanted tumors in every group.
3 Results
3.1 Experiments in Vitro
As compared with normal control group (control-1) at the same time, OD value was decreased significantly(P< 0.05 or 0.01)in seven different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group, Tet-6 group, Tet-8 group, Tet-16 group),and OD value decreased more significantly as Tet concentration increased. The inhibitory rate of Tet was enlarged with the increase of the concentration in the same time, which exhibited dose-effect relationship. With the passage of time, inhibitory effect of Tet on MDA-MB-435S cell in vitro growth was enlarged, which exhibited time-dependent effect. Interaction effect of dose and time existed for the effect of Tet on MDA-MB-435S cell (P<0.01). IC50 value in 24h,48h,72h,96h were 8.748μg/ml,3.585μg/ml, 1.451μg/ml,1.117μg/ml respectively.
As compared with normal control group in the same phase, cell percentage of S phase, G2M phase in MDA-MB-435S cell were decreased significantly in four different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group) after administration for 24h, with statistical significance (P< 0.05).Higher the Tet concentration, lower the cell percentage of S phase, G2M phase. As compared with normal control group in the same phase, cell percentage of Go/Gi phase were increased significantly, with statistical significance (P < 0.05). Higher the Tet concentration, higher the cell percentage of G0/G1 phase.
As compared with control-1 group after administration for 24h, early apoptosis rate was increased in four different Tet concentration groups (Tet-0.5 group, Tet-1 group, Tet-2 group, Tet-4 group),with statistical significance (P< 0.05). As compared with control-1 group after administration for 48h, early apoptosis rate was increased significantly in Tet-1 group, Tet-2 group and Tet-4 group (P< 0.05).Significant positive correlation was observed between early apoptosis rate and Tet concentration after administration for 24h,48h (P<0.05). With the passage of time, early apoptosis rate were increased gradually. There were no difference in late apoptosis rate between Tet groups and control-1 group after administration for 24h(P> 0.05). As compared with control-1 group after administration for 48h, late apoptosis rate were increased gradually in Tet high-concentration groups, with statistical significance (P< 0.05).
3.2 Experiments in Vivo
From 6 days after treatment, volumes of transplanted tumor in Tet group and positive control group were significantly smaller than model group (P<0.05 or 0.01), there were no difference between Tet group and positive control group (P> 0.05).The weight of the transplanted tumor in Tet group and positive control group were significantly decreased than model group (P<0.05 or 0.01) but there were no difference between Tet group and positive control group (P> 0.05). Tumor inhibitory rate in Tet group and positive control group were 25.47% and 30.43% respectively. Transplanted tumor in Tet group and positive control group by hemotoxylin and eosin staining suggested that necrotic cells and incomplete necrotic cells were seen among the adenocarcinoma. More apoptotic cells were found in Tet group and positive control group than model group. It was found by TEM that there were many apoptotic bodies in Tet group.
As compared with model group, the positive cell area, mean optical density and immunohistochemistry index of Bcl-2 in Tet group and positive control group were significantly reduced (P<0.05 or 0.01). As compared with model group, the positive cell area and immunohistochemistry index of Bax in Tet group and positive control group were significantly increased (P<0.01). There were no difference of mean optical density between Tet group and positive control group (P>0.05). As compared with model group, the positive cell area and immunohistochemistry index of Survivin in Tet group and positive control group were significantly reduced (P<0.01). There were no difference of mean optical density among three groups (P>0.05). As compared with model group, the positive cell area, mean optical density and immunohistochemistry index of VEGF in Tet group and positive control group were significantly reduced (P<0.01),but There were no difference between Tet group and positive control group (P> 0.05).
4 Conclusion
(1) It is first found that the effect of Tet on inhibiting ER negative breast cancer MDA-MB-435S cell proliferation is obvious, which provides the basic research data for clinical treatments on ER negative breast cancer.
(2) Tet can induce the early apoptosis after administration for 24h,48h. There is significant positive correlation between early apoptosis rate and Tet concentration.It has concentration and time dependence in the range of 0.5μg /ml to 4μg/ml.
(3)Blocking the cell cycle at G0/G1 phase and reducing the cell percentage of S phase to inhibit the DNA synthesis is one of the antitumor mechanisms of Tet on breast cancer cell in Vitro.
(4)Tet can inhibit the growth of transplanted tumor of MCF-7 in nude mice.
(5)The antitumor mechanisms of Tet on MCF-7 in tumor bearing nude mice are related to reducing Bcl-2, Survivin, VEGF protein expression and increasing Bax protein expression.
引文
[1]张文娟.乳岩证治的中医文献研究[D].山东中医药大学硕士学位论文,2008.
[2]毕丽娟,司富春,王峰.古代治疗乳岩的方药分析[J].时珍国医国药,2006,17(4)：656～657.
[3]陈丽,叶丽红.乳腺癌手术前后的病证分型[J].长春中医药大学学报,2008,24(3)：276～277.
[4]刘胜,陆德铭,唐汉钧,等.试论乳腺癌痰毒瘀结病机的理论基础与临床应用[J].中西医结合学报,2007,5(2)：4～8.
[5]晋·葛洪.肘后备急方[M].北京：人民卫生出版社,1983.
[6]隋·巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社,1997.
[7]明·王肯堂.证治准绳[M].上海：上海科学技术出版社,1984.
[8]明·陈实功.外科正宗[M].上海：上海科学技术出版社,1989.
[9]元·朱震亨.丹溪心法[M].沈阳：辽宁科学技术出版社,1997.
[1]唐汉钧.乳腺癌的中医临床与实验研究[J].中医中药学刊,2003,21(2)：168.
[2]孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2007：425.
[3]司徒红林,陈前军,林毅,等.乳腺癌围手术期患者中医证型及转化规律的临床研究[J].中华中医药学刊,2009,27(12)：2568～2570.
[4]刘抒玉,殷东风.中医药治疗乳腺癌92例临床观察[J].吉林中医药,2008,28(5)：333～334.
[5]徐少峰.乳腺癌的中医药治疗临床观察[J].中国现代药物应用,2008,2(22)：73～74.
[6]龚贵川.中医治疗乳腺癌根治术后创面不愈2例[J].四川中医,2007,27(8)：80.
[7]刘红梅,卞卫和,任晓梅,等.乳腺癌术后并发症的中医治疗[J].四川中医,2007,25(6)：85～86.
[8]吴玉华,万冬桂.当归芍药散加味治疗乳腺癌术后同侧上肢肿胀38例[J].中医药学报,2003,31(1)：45.
[9]唐汉钧,高尚璞,郑勇,等.中医药治疗乳腺癌术后患者288例临床观察[J].上海中医药大学学报,2002,16(3)：23～24.
[10]罗雪冰.益气祛邪汤治疗乳腺癌术后76例疗效观察[J].华夏医学,2007,20(2)：247～248.
[11]任黎萍,李娟娟.100例乳腺癌术后疲劳综合征中医辨证规律探析[J].陕西中医,2008,29(7)：798～800.
[12]胡升芳,陈红风,秦悦农,等.乳宁Ⅱ号方防治乳腺癌术后复发转移临床疗效评价[J].中华中医药学刊,2009,27(11)：2396～2398.
[13]林毅,陈前军,刘鹏熙.乳腺癌分期辨证规范化——一个中医乳房病学与时俱进的重要课题[J].中西医结合学报,2006,4(5)：447～450.
[14]刘武,林秋菊,莫澎涛.扶正培本对乳腺癌新辅助化疗患者免疫功能的影响[J].北京中医药大学学报(中医临床版),2008,15(6)：11～12.
[15]黄智芬,韦劲松,黎汉忠,等.参芪扶正注射液联合化疗治疗晚期乳腺癌30例临床观察[J].中国中西医结合杂志,2008,28(2)：152～154.
[16]郭勇,姚庆华,杨维泓,等.益气健脾法干预乳腺癌患者化疗所致脾虚证的临床研究[J].中华中医药学刊,2007,25(12)：2443-2446.
[17]杨国旺,徐咏梅,富琦,等.固本抑瘤Ⅱ号联合化疗治疗晚期乳腺癌28例临床观察[J].中医杂志,2008,49(12)：1081～1083.
[18]周浩本.中药防治乳腺癌化疗消化道反应[J].医药产业资讯,2005,2(11)：63.
[19]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察[J].中医药临床杂志,2005,17(1)：15～16.
[20]卢雯平,陈长怀,花宝金,等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12(6)：331～333.
[21]李明瑞.肝脾肾同治在乳腺癌治疗中的应用浅析[J].陕西中医,2006,27(2)：191～192.
[22]刘鹏熙,林毅,陈前军,等.乳腺癌围手术期中医药参与治疗的若干问题探讨[J].中西医结合学报,2005,3(3)：178～180.
[23]杨婧,张捷,王笑民,等.乳腺癌伴发抑郁焦虑患者的中医证型分析[J].中医杂志,2009,50(12)：1112～1116.
[24]陈良珠,谢忠,冯湛华,等.乳腺癌患者的焦虑抑郁情绪测定及其中医对策[J].齐齐哈尔医学院学报,2002,23(8)：886～887.
[25]贾喜花,高尚璞,郑勇,等.唐汉钧治疗乳腺癌经验[J].中医杂志,2003,44(2)：96～97.
[26]陈军,贾英杰,孙一予,等.中医立体疗法提高术后乳腺癌患者生存质量临床研究[J].辽宁中医杂志,2007,34(8)：1093-1094.
[27]刘晓雁,李宁秀,林毅,等.影响乳腺癌患者术后生活质量的多因素分析[J].中国临床康复,2004,8(35)：7885～7887.
[28]陈明燕,陈良良.中医药治疗对乳腺癌患者生活质量的影响[J].甘肃中医,2009,22(2)：19～21.
[29]刘鲁明,于尔辛.中西医结合抗肿瘤治疗[J].抗癌,2006,21(3)：18～19.
[30]司徒红林,陈前军,朱华宇.林毅教授辨治乳腺癌经验介绍[J].新中医,2008,40(7)：5～6.
[31]沈晔华,宋明志,黄雯霞.中西医结合治疗71例乳腺癌术后患者的疗效分析[J].中西医结合学报,2003,1(1)：30～31.
[32]李仕金.乳腺癌系统治疗与生存关系的探讨[J].中国中医中药信息杂志,2006,13(5)：79～80.
[33]池慧珍,林胜友.中医中药在乳腺癌化疗中的研究进展[J].陕西中医学院学报,2009,32(2)：70～72.
[1]Kwan CY, Achike FI. Tetrandrine and related bisbenzylisoquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of actions [J]. Acta Pharmacol Sin,2002,23 (12):1057-1068.
[2]陈宝安,王为,林国为.汉防已甲素在肿瘤治疗中的研究进展[J].中国中西医结合杂志,2001,21(8)：636～638.
[3]Hickman JA. Apoptosis induced by anticancer drug[J]. Cancer Metastasis Rev,1992,11(1):121-139.
[4]Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis [J].Proc Natl Acad Sci USA,1998,95 (12):7024-7029.
[5]Robinson LJ, Roberts WK, Lamming D, et al. Human MDR1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts [J]. Biochemistry,1997,36 (37):11169-11178.
[6]王金华,叶祖光,孙爱续,等.粉防已碱逆转耐阿霉素的人乳腺癌MCF-7细胞的抗凋亡作用[J].中国组织化学与细胞化学杂志,2000,9(4)：436～440.
[7]王金华,叶祖光,孙爱续,等.粉防已碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1)：46～50.
[8]叶祖光,孙爱续,李兰芳,等.汉防已甲素对阿霉素或长春新碱耐药株人癌细胞的逆转抗药性作用[J].中国中药杂志,1996,21(6)：369～371.
[9]叶祖光,王金华,孙爱续,等.粉防已碱、甲基莲心碱和蝙蝠葛碱增强长春新碱诱导人乳腺癌MCF-7多药耐药细胞凋亡[J].药学学报,2001,36(2)：96～99.
[10]符立梧,潘启超,黄红兵,等.粉防已碱逆转肿瘤多药抗药性细胞的凋亡抗性作用[J].中国药理学通报,1998,14(4)：309～311.
[11]符立梧,潘启超,梁永钜,等.粉防已碱逆转肿瘤多药抗药性作用及其机理的研究[J].第四届中国新医药博士论坛论文集,1999：301～308.
[12]Fu LW, Deng ZA, FanW. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzy lisoquinoline alkaloids [J]. Anticancer Res,2001, 21 (4A):2273.
[13]Fu LW, ZhangYM, LiangYJ.Multidrug resistance of tumor cells was reversed by tetrandrine in vitro and in xenograf t derived from human breast cancer MCF-7/adr cells [J]. Eur. J. Cancer,2002,38 (3):418.
[14]孙新臣,王俊杰,甄永苏,等.粉防已碱增加人乳腺癌细胞对X射线敏感性及其机理研 究[J].中华放射医学与防护杂志,2003,23(3)：160～162.
[15]裴晓华,许芝银.粉防已碱对乳腺癌细胞系生长的影响[J].解剖学报,2001,32(1)：37.
[16]裴晓华,樊英怡.粉防已碱对人乳腺癌细胞MCF-7细胞株的作用[J].河南中医学院学报,2007,22(5)：12～15.
[17]裴晓华,樊英怡.三氧化二砷与粉防已碱联合作用诱导MCF-7细胞凋亡的作用[J].2008年中医外科学术年会论文集,2008：134-138.
[18]韩晓兵,柳友清,卢运萍,等.粉防已碱对人卵巢癌细胞株A2780增殖与凋亡的影响[J].中国肿瘤临床,2006,33(4)：190～193.
[19]汤艳,任盛萍.粉防已碱抑制人卵巢癌HO-8910细胞生长的研究[J].辽宁医学院学报,2007,28(6)：29～31.
[20]邢艳霞,郭洁群,邓文英.粉防已碱对人宫颈癌Hela细胞增殖与凋亡的影响[J].中国现代医学杂志,2009,19(2)：292～295.
[21]徐和平,王成业,祝和成.汉防已甲素和长春新碱对人视网膜母细胞瘤细胞系HXO-Rb44生长的抑制作用[J].中国中医眼科杂志,1995,5(2)：67～69.
[22]徐和平,王成业,祝和成.汉防已甲素对视网膜母细胞瘤细胞系HXO-Rb44放射敏感性的影响[J].中国实用眼科杂志,1995,13(11)：668.
[23]雷宁,涂勤,刘碧崇.粉防已碱与表阿霉素联用对表阿霉素在荷瘤裸鼠血、心与肿瘤组织浓度的影响[J].四川生理科学杂志,2006,28(3)：128～130.
[24]陈晓松.粉防已碱对人口腔上皮癌多药耐药细胞株KB-MRP1多药耐药性的逆转作用.安徽医科大学硕士学位论文,2007年.
[25]邓雨霞,孙新臣.粉防已碱对人鼻咽癌细胞株CNE增殖抑制和凋亡作用的研究[J].医学研究生学报,2007,20(4)：360～365.
[26]孙新臣,邓雨霞,成红艳,等.粉防已碱对人鼻咽癌CNE细胞凋亡作用和增加其对X射线敏感性的研究[J].2007医学前沿论坛暨第十届全国肿瘤药理与化疗学术会议论文集,2007：124.
[27]邓碧.阿霉素-粉防已碱脂质体对人鼻咽癌耐药细胞株HNE-1／ADM逆转作用的实验研究.重庆医科大学,硕士学位论文,2009年.
[28]叶琳,王驰,陈鸿雁,等.氧化苦参碱和粉防已碱对鼻咽癌耐药细胞株的耐药逆转作用[J].第四军医大学学报,2009,30(11)：967～970.
[29]叶琳.粉防已碱对喉癌耐药细胞株Hep-2／ADM的耐药逆转作用及可能机制研究.重庆医科大学,硕士学位论文,2008年.
[30]叶琳,陈鸿雁.粉防已碱对喉癌耐药细胞株KBV200耐药逆转作用的研究[J].重庆医科大学学报,2008,33(8)：967～969.
[31]KUO PL, LIN CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells [J]. Life Sciences,2003,73(2):243-252.
[32]NG LT, CHIANG LC,LIN YT. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines[J]. The American Journal of Chinese Medicine,2006,34(1):125-135.
[33]邓文英,孙新臣,李苏宜.粉防已碱对人肝癌7402细胞株增殖与凋亡的影响[J].医学研究生学报,2007,20(2)：138～141.
[34]邓文英,罗素霞,周孟强,等.粉防已碱联合奈达铂抗人肝癌7402细胞作用的实验研究[J].中药材,2008,31(10)：1522～1525.
[35]孙新臣,邓文英,李苏宜,等.粉防已碱对人肝癌细胞株7402的放射增敏作用[J].临床肿瘤学杂志,2007,12(12)：893～901.
[36]Lee JH,Kang GH, Kim KC, et al. Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells [J].Int J Oncol,2002,21 (6):1239-1244.
[37]徐萌,周蓓.汉防已甲素逆转肺癌化疗耐药和凋亡抗性的实验研究[J].新中医,2006,38(6)：90.
[38]陈辉,王文忠,丁劲松,等.粉防已碱诱导人肺腺癌细胞SPC-A-1凋亡的机制[J].实用医学杂志,2009,25(19)：3187～3189.
[39]邓文英,罗素霞,周孟强,等.粉防已碱对人结肠癌细胞株HT-29增殖与凋亡的影响[J].实用医学杂志,2008,24(19)：3288-3290.
[40]吴浩,张正,杨锦林,等.粉防已碱对人结肠癌细胞增殖的影响[J].现代中西医结合杂志,2009,9(19)：1853～1855.
[41]陈绚丽.粉防已碱诱导肿瘤细胞周期阻滞和细胞凋亡的分子机制及其信号传导通路研究.北京协和医学院中国医学科学院,博士研究生学位论文,2008年.
[42]孙新臣,王俊杰,甄永苏.粉防已碱对放射线的增敏作用与机理研究[J].中华放射医学与防护杂志,2004,24(2)：99～101.
[43]李永生,陈仕平,杨罗艳,等.粉防已碱抑制人膀胱移行细胞癌BIU-87细胞生长的研究[J].福建中医学院学报,2005,15(3)：25～27.
[44]陈宝安,周云,程坚,等.蛋白激酶C与K562／A02细胞多药耐药相关性的研究.白血病·淋巴瘤,2005,14：7～9.
[45]陈宝安,董颖,张鹏等.汉防已甲素联合屈洛昔芬逆转K562／A02细胞多药耐药的研究.中华血液学杂志,2002,23：660～661.
[46]陈宝安,李静,程坚,等.汉防已甲素联合柔红霉素对K562／A02细胞株P21蛋白和P糖蛋白表达的影响.中国实验血液学杂志,2009,17(5)：1179～1182.
[47]陈宝安,苏爱玲,程坚,等.汉防已甲素对白血病耐药细胞株K562／A02核因子κB表达的影响.中西医结合学报,2008,6(9)：956～959.
[48]赵殿凤,刘子玲,马宁,等.汉防已甲素逆转白血病细胞株K562／A02耐药的机制.吉林大学学报,2009,35(1)：100～103.
[49]吕旭晶.汉防已甲素干预白血病细胞获得性多药耐药的研究.江苏大学硕士学位论文,2008.
[50]郭晶晶,陈宝安,高峰,等.环孢菌素A、汉防已甲素及两者联合逆转K562／A02细胞的多药耐药.东南大学学报,2008,27(2)：82～86.
[51]狄凯军,周建平,章静波.粉防已碱诱导人红白血病细胞凋亡的研究[J].解剖学报,2002,33(5)：531.
[52]许文林,钱军,费霞.汉防已甲素逆转血液系统肿瘤细胞多药耐药的临床观察[J].中华血液学杂志,1999,20(7)：383.
[53]Xu WL, Shen HL,Ao ZF. Combination of tetrandrine as a potential reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acutemyelogenous leukemia[J]. Leukemia Research,2006,30(4):407.
[1]郭仕华,姿红祥,贺艳丽.天然抗肿瘤药物的研究进展[J].国外医药·植物药分册,2005,20(5)：190-191.
[2]杨契,韩为东,赵亚力.乳腺癌与雌激素及有关内分泌治疗[J].现代肿瘤医学,2007,15(5)：729～730.
[3]杨红斌,付京,张盈华,等.乳腺癌组织中孕激素受体与雌激素受体DNA结合功能关系的研究[J].中国肿瘤临床,1999,26(10)：743～746.
[4]中华本草编委会编.《中华本草》[M].上海：上海科学技术出版社,1998：585.
[5]Kwan CY, Achike FI. Tetrandrine and related bisbenzylisoquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of actions [J]. Acta Pharmacol Sin,2002,23 (12):1057-1068.
[6]Lai YL,Chen YJ,Wu TY. Induction of apoptosis in human leukemic U937 cells by tetrandrine[J]. Anticancer Drugs,1998,9 (1):77-81.
[7]王金华,叶祖光,孙爱续,等.粉防已碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1)：46～49.
[8]Chen YJ,Dai YS, Chec BF. The effect of tetrandrine and extracts of centella asiatice on acute radiation dermatitis in rats[J].Biol Pharm Bull,1999,22 (7): 703.
[9]孙新臣,王俊杰,甄永苏,等.粉防已碱增加人乳腺癌细胞对X射线敏感性及其机理研究[J].中华放射医学与防护杂志,2003,23(3)：160.
[10]赵斌,葛金芳,朱娟娟,等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834～836.
[11]周一平.用SPSS软件计算新药的LD50[J].药学进展,2003,27(5)：314～316.
[12]司徒镇强,吴军正.主编.细胞培养[M].西安：世界图书出版公司,2001：200.
[13]裴晓华,许芝银.粉防已碱对乳腺癌细胞系生长的影响[J].解剖学报,2001,32(1)：37.
[14]汤艳,任盛萍.粉防已碱抑制人卵巢癌HO-8910细胞生长的研究[J].辽宁医学院学报,2007,28(6)：29～31.
[15]徐和平,王成业,祝和成.汉防已甲素和长春新碱对人视网膜母细胞瘤细胞系HXO-Rb44生长的抑制作用[J].中国中医眼科杂志,1995,5(2)：67～69.
[16]邓雨霞,孙新臣.粉防已碱对人鼻咽癌细胞株CNE增殖抑制和凋亡作用的研究[J].医学研究生学报,2007,20(4)：360～365.
[17]NG LT, CHIANG LC,LIN YT. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines [J]. The American Journal of Chinese Medicine,2006,34 (1):125-135.
[18]KUO PL, LIN CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells [J]. Life Sciences,2003,73 (2):243-252.
[19]邓文英,孙新臣,李苏宜.粉防已碱对人肝癌7402细胞株增殖与凋亡的影响[J].医学研究生学报,2007,20(2)：138～141.
[20]邓文英,罗素霞,周孟强,等.粉防已碱对人结肠癌细胞株HT-29增殖与凋亡的影响[J].实用医学杂志,2008,24(19)：3288～3290.
[21]吴浩,张正,杨锦林,等.粉防已碱对人结肠癌细胞增殖的影响[J].现代中西医结合杂志,2009,9(19)：1853～1855.
[22]李永生,陈仕平,杨罗艳,等.粉防已碱抑制人膀胱移行细胞癌BIU-87细胞生长的研究[J].福建中医学院学报,2005,15(3)：25～27.
[23]张文彤,闫洁.SPSS统计分析基础教程.北京：高等教育出版社,2005：289～292.
[24]高慧,傅松滨,董辉.肿瘤中p16基因的研究进展.国外医学遗传学分册,1999,22(2)：64.
[25]陈辉,王文忠,丁劲松,等.粉防已碱诱导人肺腺癌细胞SPC-A-1凋亡的机制[J].实用医学杂志,2009,25(19)：3187～3189.
[26]韩晓兵,柳友清,卢运萍,等.粉防已碱对人卵巢癌细胞株A2780增殖与凋亡的影响[J].中国肿瘤临床,2006,33(4)：190～193.
[27]陈宝安,王为,林国为.汉防已甲素抗肿瘤作用的研究进展[J].南京中医药大学学报(自然科学版),2001,17(2)：128-130.
[28]余微波,谷俊朝.乳腺癌动物模型的建立[J].国外医学外科学分册,2005,32(1)：63～66.
[29]李文生,姜德咏,丁建光,等.吲哚美辛诱导视网膜色素上皮细胞凋亡的实验研究[J].中国临床康复,2004,8(20)：4126-4127.
[30]Conway EM, Pollefeyt S, Steiner-Mosonyi M, et al. Deficiency of surviving in transgenic mice exacerbates Fas induced apoptosis via mitochondria pathways [J]. Gastroenterology,2002,123 (2):619-631.
[31]Altieri DC. The molecular basis and potential role of surviving in cancer diagnosis and therapy [J].Trends Mol Med,2001,7(12):542-547.
[32]吴炅,沈镇宙.乳腺癌中Bcl-2基因族研究现状[J].中国癌症杂志,1998,8(3)：217～221.
[33]Li Y,Bhuiyan M,Mohammad RM,et al. Induction of apoptosis in breast cancer cells by TPA[J]. Oncogene,1998,17(22):2915-2920.
[34]Rosse T, Olivier R,Monnery L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c[J]. Nature,1998,391 (1):496-499.
[35]Ambrosini G,Adida C, Altieri DC. A novel anti-apoptosis gene survivin expressed in cancer and lymphoma[J]. Nature Med,1997,3(8):917-921.
[36]沙玉英,徐国光.Survivin和细胞周期蛋白Dl在乳腺癌中表达的临床意义[J].南通医学院学报,2004,24(3)269～270.
[37]Keitaro Tanaka, Shinji Iwamato,Goke Gon, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas [J]. Clinical Cancer Research,2000,1(6):127-134.
[38]Tamm I, Wang Y, Sausville E, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs [J]. CancerRes,1998,58:5315-5320.
[39]Shin S,Sung BJ,Cho YS,et al.An anti-apoptotic protein human Survivin is a direct inhibitor of caspase-3 and caspase-7 [J]. Biochemistry,2001,40:1117-1123.
[40]Takahashi Y,Kitadai Y, Bucana CD, et al.Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer[J].Cancer Res,1995, 55 (18):3964-3968.
[41]Salven P, Lymboussaki A, Heikkila P, et al.Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumors[J]. Am J Pathol,1998, 153 (1):103-108.
[42]邓俊芳.和厚朴酚抗胰腺癌作用及其机制的实验研究[D].浙江大学博士学位论文,2008：73.
[2]毕丽娟,司富春,王峰.古代治疗乳岩的方药分析[J].时珍国医国药,2006,17(4)：656～657.
[3]陈丽,叶丽红.乳腺癌手术前后的病证分型[J].长春中医药大学学报,2008,24(3)：276～277.
[4]刘胜,陆德铭,唐汉钧,等.试论乳腺癌痰毒瘀结病机的理论基础与临床应用[J].中西医结合学报,2007,5(2)：4～8.
[5]晋·葛洪.肘后备急方[M].北京：人民卫生出版社,1983.
[6]隋·巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社,1997.
[7]明·王肯堂.证治准绳[M].上海：上海科学技术出版社,1984.
[8]明·陈实功.外科正宗[M].上海：上海科学技术出版社,1989.
[9]元·朱震亨.丹溪心法[M].沈阳：辽宁科学技术出版社,1997.
[1]唐汉钧.乳腺癌的中医临床与实验研究[J].中医中药学刊,2003,21(2)：168.
[2]孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2007：425.
[3]司徒红林,陈前军,林毅,等.乳腺癌围手术期患者中医证型及转化规律的临床研究[J].中华中医药学刊,2009,27(12)：2568～2570.
[4]刘抒玉,殷东风.中医药治疗乳腺癌92例临床观察[J].吉林中医药,2008,28(5)：333～334.
[5]徐少峰.乳腺癌的中医药治疗临床观察[J].中国现代药物应用,2008,2(22)：73～74.
[6]龚贵川.中医治疗乳腺癌根治术后创面不愈2例[J].四川中医,2007,27(8)：80.
[7]刘红梅,卞卫和,任晓梅,等.乳腺癌术后并发症的中医治疗[J].四川中医,2007,25(6)：85～86.
[8]吴玉华,万冬桂.当归芍药散加味治疗乳腺癌术后同侧上肢肿胀38例[J].中医药学报,2003,31(1)：45.
[9]唐汉钧,高尚璞,郑勇,等.中医药治疗乳腺癌术后患者288例临床观察[J].上海中医药大学学报,2002,16(3)：23～24.
[10]罗雪冰.益气祛邪汤治疗乳腺癌术后76例疗效观察[J].华夏医学,2007,20(2)：247～248.
[11]任黎萍,李娟娟.100例乳腺癌术后疲劳综合征中医辨证规律探析[J].陕西中医,2008,29(7)：798～800.
[12]胡升芳,陈红风,秦悦农,等.乳宁Ⅱ号方防治乳腺癌术后复发转移临床疗效评价[J].中华中医药学刊,2009,27(11)：2396～2398.
[13]林毅,陈前军,刘鹏熙.乳腺癌分期辨证规范化——一个中医乳房病学与时俱进的重要课题[J].中西医结合学报,2006,4(5)：447～450.
[14]刘武,林秋菊,莫澎涛.扶正培本对乳腺癌新辅助化疗患者免疫功能的影响[J].北京中医药大学学报(中医临床版),2008,15(6)：11～12.
[15]黄智芬,韦劲松,黎汉忠,等.参芪扶正注射液联合化疗治疗晚期乳腺癌30例临床观察[J].中国中西医结合杂志,2008,28(2)：152～154.
[16]郭勇,姚庆华,杨维泓,等.益气健脾法干预乳腺癌患者化疗所致脾虚证的临床研究[J].中华中医药学刊,2007,25(12)：2443-2446.
[17]杨国旺,徐咏梅,富琦,等.固本抑瘤Ⅱ号联合化疗治疗晚期乳腺癌28例临床观察[J].中医杂志,2008,49(12)：1081～1083.
[18]周浩本.中药防治乳腺癌化疗消化道反应[J].医药产业资讯,2005,2(11)：63.
[19]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察[J].中医药临床杂志,2005,17(1)：15～16.
[20]卢雯平,陈长怀,花宝金,等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12(6)：331～333.
[21]李明瑞.肝脾肾同治在乳腺癌治疗中的应用浅析[J].陕西中医,2006,27(2)：191～192.
[22]刘鹏熙,林毅,陈前军,等.乳腺癌围手术期中医药参与治疗的若干问题探讨[J].中西医结合学报,2005,3(3)：178～180.
[23]杨婧,张捷,王笑民,等.乳腺癌伴发抑郁焦虑患者的中医证型分析[J].中医杂志,2009,50(12)：1112～1116.
[24]陈良珠,谢忠,冯湛华,等.乳腺癌患者的焦虑抑郁情绪测定及其中医对策[J].齐齐哈尔医学院学报,2002,23(8)：886～887.
[25]贾喜花,高尚璞,郑勇,等.唐汉钧治疗乳腺癌经验[J].中医杂志,2003,44(2)：96～97.
[26]陈军,贾英杰,孙一予,等.中医立体疗法提高术后乳腺癌患者生存质量临床研究[J].辽宁中医杂志,2007,34(8)：1093-1094.
[27]刘晓雁,李宁秀,林毅,等.影响乳腺癌患者术后生活质量的多因素分析[J].中国临床康复,2004,8(35)：7885～7887.
[28]陈明燕,陈良良.中医药治疗对乳腺癌患者生活质量的影响[J].甘肃中医,2009,22(2)：19～21.
[29]刘鲁明,于尔辛.中西医结合抗肿瘤治疗[J].抗癌,2006,21(3)：18～19.
[30]司徒红林,陈前军,朱华宇.林毅教授辨治乳腺癌经验介绍[J].新中医,2008,40(7)：5～6.
[31]沈晔华,宋明志,黄雯霞.中西医结合治疗71例乳腺癌术后患者的疗效分析[J].中西医结合学报,2003,1(1)：30～31.
[32]李仕金.乳腺癌系统治疗与生存关系的探讨[J].中国中医中药信息杂志,2006,13(5)：79～80.
[33]池慧珍,林胜友.中医中药在乳腺癌化疗中的研究进展[J].陕西中医学院学报,2009,32(2)：70～72.
[1]Kwan CY, Achike FI. Tetrandrine and related bisbenzylisoquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of actions [J]. Acta Pharmacol Sin,2002,23 (12):1057-1068.
[2]陈宝安,王为,林国为.汉防已甲素在肿瘤治疗中的研究进展[J].中国中西医结合杂志,2001,21(8)：636～638.
[3]Hickman JA. Apoptosis induced by anticancer drug[J]. Cancer Metastasis Rev,1992,11(1):121-139.
[4]Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis [J].Proc Natl Acad Sci USA,1998,95 (12):7024-7029.
[5]Robinson LJ, Roberts WK, Lamming D, et al. Human MDR1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts [J]. Biochemistry,1997,36 (37):11169-11178.
[6]王金华,叶祖光,孙爱续,等.粉防已碱逆转耐阿霉素的人乳腺癌MCF-7细胞的抗凋亡作用[J].中国组织化学与细胞化学杂志,2000,9(4)：436～440.
[7]王金华,叶祖光,孙爱续,等.粉防已碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1)：46～50.
[8]叶祖光,孙爱续,李兰芳,等.汉防已甲素对阿霉素或长春新碱耐药株人癌细胞的逆转抗药性作用[J].中国中药杂志,1996,21(6)：369～371.
[9]叶祖光,王金华,孙爱续,等.粉防已碱、甲基莲心碱和蝙蝠葛碱增强长春新碱诱导人乳腺癌MCF-7多药耐药细胞凋亡[J].药学学报,2001,36(2)：96～99.
[10]符立梧,潘启超,黄红兵,等.粉防已碱逆转肿瘤多药抗药性细胞的凋亡抗性作用[J].中国药理学通报,1998,14(4)：309～311.
[11]符立梧,潘启超,梁永钜,等.粉防已碱逆转肿瘤多药抗药性作用及其机理的研究[J].第四届中国新医药博士论坛论文集,1999：301～308.
[12]Fu LW, Deng ZA, FanW. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzy lisoquinoline alkaloids [J]. Anticancer Res,2001, 21 (4A):2273.
[13]Fu LW, ZhangYM, LiangYJ.Multidrug resistance of tumor cells was reversed by tetrandrine in vitro and in xenograf t derived from human breast cancer MCF-7/adr cells [J]. Eur. J. Cancer,2002,38 (3):418.
[14]孙新臣,王俊杰,甄永苏,等.粉防已碱增加人乳腺癌细胞对X射线敏感性及其机理研 究[J].中华放射医学与防护杂志,2003,23(3)：160～162.
[15]裴晓华,许芝银.粉防已碱对乳腺癌细胞系生长的影响[J].解剖学报,2001,32(1)：37.
[16]裴晓华,樊英怡.粉防已碱对人乳腺癌细胞MCF-7细胞株的作用[J].河南中医学院学报,2007,22(5)：12～15.
[17]裴晓华,樊英怡.三氧化二砷与粉防已碱联合作用诱导MCF-7细胞凋亡的作用[J].2008年中医外科学术年会论文集,2008：134-138.
[18]韩晓兵,柳友清,卢运萍,等.粉防已碱对人卵巢癌细胞株A2780增殖与凋亡的影响[J].中国肿瘤临床,2006,33(4)：190～193.
[19]汤艳,任盛萍.粉防已碱抑制人卵巢癌HO-8910细胞生长的研究[J].辽宁医学院学报,2007,28(6)：29～31.
[20]邢艳霞,郭洁群,邓文英.粉防已碱对人宫颈癌Hela细胞增殖与凋亡的影响[J].中国现代医学杂志,2009,19(2)：292～295.
[21]徐和平,王成业,祝和成.汉防已甲素和长春新碱对人视网膜母细胞瘤细胞系HXO-Rb44生长的抑制作用[J].中国中医眼科杂志,1995,5(2)：67～69.
[22]徐和平,王成业,祝和成.汉防已甲素对视网膜母细胞瘤细胞系HXO-Rb44放射敏感性的影响[J].中国实用眼科杂志,1995,13(11)：668.
[23]雷宁,涂勤,刘碧崇.粉防已碱与表阿霉素联用对表阿霉素在荷瘤裸鼠血、心与肿瘤组织浓度的影响[J].四川生理科学杂志,2006,28(3)：128～130.
[24]陈晓松.粉防已碱对人口腔上皮癌多药耐药细胞株KB-MRP1多药耐药性的逆转作用.安徽医科大学硕士学位论文,2007年.
[25]邓雨霞,孙新臣.粉防已碱对人鼻咽癌细胞株CNE增殖抑制和凋亡作用的研究[J].医学研究生学报,2007,20(4)：360～365.
[26]孙新臣,邓雨霞,成红艳,等.粉防已碱对人鼻咽癌CNE细胞凋亡作用和增加其对X射线敏感性的研究[J].2007医学前沿论坛暨第十届全国肿瘤药理与化疗学术会议论文集,2007：124.
[27]邓碧.阿霉素-粉防已碱脂质体对人鼻咽癌耐药细胞株HNE-1／ADM逆转作用的实验研究.重庆医科大学,硕士学位论文,2009年.
[28]叶琳,王驰,陈鸿雁,等.氧化苦参碱和粉防已碱对鼻咽癌耐药细胞株的耐药逆转作用[J].第四军医大学学报,2009,30(11)：967～970.
[29]叶琳.粉防已碱对喉癌耐药细胞株Hep-2／ADM的耐药逆转作用及可能机制研究.重庆医科大学,硕士学位论文,2008年.
[30]叶琳,陈鸿雁.粉防已碱对喉癌耐药细胞株KBV200耐药逆转作用的研究[J].重庆医科大学学报,2008,33(8)：967～969.
[31]KUO PL, LIN CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells [J]. Life Sciences,2003,73(2):243-252.
[32]NG LT, CHIANG LC,LIN YT. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines[J]. The American Journal of Chinese Medicine,2006,34(1):125-135.
[33]邓文英,孙新臣,李苏宜.粉防已碱对人肝癌7402细胞株增殖与凋亡的影响[J].医学研究生学报,2007,20(2)：138～141.
[34]邓文英,罗素霞,周孟强,等.粉防已碱联合奈达铂抗人肝癌7402细胞作用的实验研究[J].中药材,2008,31(10)：1522～1525.
[35]孙新臣,邓文英,李苏宜,等.粉防已碱对人肝癌细胞株7402的放射增敏作用[J].临床肿瘤学杂志,2007,12(12)：893～901.
[36]Lee JH,Kang GH, Kim KC, et al. Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells [J].Int J Oncol,2002,21 (6):1239-1244.
[37]徐萌,周蓓.汉防已甲素逆转肺癌化疗耐药和凋亡抗性的实验研究[J].新中医,2006,38(6)：90.
[38]陈辉,王文忠,丁劲松,等.粉防已碱诱导人肺腺癌细胞SPC-A-1凋亡的机制[J].实用医学杂志,2009,25(19)：3187～3189.
[39]邓文英,罗素霞,周孟强,等.粉防已碱对人结肠癌细胞株HT-29增殖与凋亡的影响[J].实用医学杂志,2008,24(19)：3288-3290.
[40]吴浩,张正,杨锦林,等.粉防已碱对人结肠癌细胞增殖的影响[J].现代中西医结合杂志,2009,9(19)：1853～1855.
[41]陈绚丽.粉防已碱诱导肿瘤细胞周期阻滞和细胞凋亡的分子机制及其信号传导通路研究.北京协和医学院中国医学科学院,博士研究生学位论文,2008年.
[42]孙新臣,王俊杰,甄永苏.粉防已碱对放射线的增敏作用与机理研究[J].中华放射医学与防护杂志,2004,24(2)：99～101.
[43]李永生,陈仕平,杨罗艳,等.粉防已碱抑制人膀胱移行细胞癌BIU-87细胞生长的研究[J].福建中医学院学报,2005,15(3)：25～27.
[44]陈宝安,周云,程坚,等.蛋白激酶C与K562／A02细胞多药耐药相关性的研究.白血病·淋巴瘤,2005,14：7～9.
[45]陈宝安,董颖,张鹏等.汉防已甲素联合屈洛昔芬逆转K562／A02细胞多药耐药的研究.中华血液学杂志,2002,23：660～661.
[46]陈宝安,李静,程坚,等.汉防已甲素联合柔红霉素对K562／A02细胞株P21蛋白和P糖蛋白表达的影响.中国实验血液学杂志,2009,17(5)：1179～1182.
[47]陈宝安,苏爱玲,程坚,等.汉防已甲素对白血病耐药细胞株K562／A02核因子κB表达的影响.中西医结合学报,2008,6(9)：956～959.
[48]赵殿凤,刘子玲,马宁,等.汉防已甲素逆转白血病细胞株K562／A02耐药的机制.吉林大学学报,2009,35(1)：100～103.
[49]吕旭晶.汉防已甲素干预白血病细胞获得性多药耐药的研究.江苏大学硕士学位论文,2008.
[50]郭晶晶,陈宝安,高峰,等.环孢菌素A、汉防已甲素及两者联合逆转K562／A02细胞的多药耐药.东南大学学报,2008,27(2)：82～86.
[51]狄凯军,周建平,章静波.粉防已碱诱导人红白血病细胞凋亡的研究[J].解剖学报,2002,33(5)：531.
[52]许文林,钱军,费霞.汉防已甲素逆转血液系统肿瘤细胞多药耐药的临床观察[J].中华血液学杂志,1999,20(7)：383.
[53]Xu WL, Shen HL,Ao ZF. Combination of tetrandrine as a potential reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acutemyelogenous leukemia[J]. Leukemia Research,2006,30(4):407.
[1]郭仕华,姿红祥,贺艳丽.天然抗肿瘤药物的研究进展[J].国外医药·植物药分册,2005,20(5)：190-191.
[2]杨契,韩为东,赵亚力.乳腺癌与雌激素及有关内分泌治疗[J].现代肿瘤医学,2007,15(5)：729～730.
[3]杨红斌,付京,张盈华,等.乳腺癌组织中孕激素受体与雌激素受体DNA结合功能关系的研究[J].中国肿瘤临床,1999,26(10)：743～746.
[4]中华本草编委会编.《中华本草》[M].上海：上海科学技术出版社,1998：585.
[5]Kwan CY, Achike FI. Tetrandrine and related bisbenzylisoquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of actions [J]. Acta Pharmacol Sin,2002,23 (12):1057-1068.
[6]Lai YL,Chen YJ,Wu TY. Induction of apoptosis in human leukemic U937 cells by tetrandrine[J]. Anticancer Drugs,1998,9 (1):77-81.
[7]王金华,叶祖光,孙爱续,等.粉防已碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1)：46～49.
[8]Chen YJ,Dai YS, Chec BF. The effect of tetrandrine and extracts of centella asiatice on acute radiation dermatitis in rats[J].Biol Pharm Bull,1999,22 (7): 703.
[9]孙新臣,王俊杰,甄永苏,等.粉防已碱增加人乳腺癌细胞对X射线敏感性及其机理研究[J].中华放射医学与防护杂志,2003,23(3)：160.
[10]赵斌,葛金芳,朱娟娟,等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834～836.
[11]周一平.用SPSS软件计算新药的LD50[J].药学进展,2003,27(5)：314～316.
[12]司徒镇强,吴军正.主编.细胞培养[M].西安：世界图书出版公司,2001：200.
[13]裴晓华,许芝银.粉防已碱对乳腺癌细胞系生长的影响[J].解剖学报,2001,32(1)：37.
[14]汤艳,任盛萍.粉防已碱抑制人卵巢癌HO-8910细胞生长的研究[J].辽宁医学院学报,2007,28(6)：29～31.
[15]徐和平,王成业,祝和成.汉防已甲素和长春新碱对人视网膜母细胞瘤细胞系HXO-Rb44生长的抑制作用[J].中国中医眼科杂志,1995,5(2)：67～69.
[16]邓雨霞,孙新臣.粉防已碱对人鼻咽癌细胞株CNE增殖抑制和凋亡作用的研究[J].医学研究生学报,2007,20(4)：360～365.
[17]NG LT, CHIANG LC,LIN YT. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines [J]. The American Journal of Chinese Medicine,2006,34 (1):125-135.
[18]KUO PL, LIN CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells [J]. Life Sciences,2003,73 (2):243-252.
[19]邓文英,孙新臣,李苏宜.粉防已碱对人肝癌7402细胞株增殖与凋亡的影响[J].医学研究生学报,2007,20(2)：138～141.
[20]邓文英,罗素霞,周孟强,等.粉防已碱对人结肠癌细胞株HT-29增殖与凋亡的影响[J].实用医学杂志,2008,24(19)：3288～3290.
[21]吴浩,张正,杨锦林,等.粉防已碱对人结肠癌细胞增殖的影响[J].现代中西医结合杂志,2009,9(19)：1853～1855.
[22]李永生,陈仕平,杨罗艳,等.粉防已碱抑制人膀胱移行细胞癌BIU-87细胞生长的研究[J].福建中医学院学报,2005,15(3)：25～27.
[23]张文彤,闫洁.SPSS统计分析基础教程.北京：高等教育出版社,2005：289～292.
[24]高慧,傅松滨,董辉.肿瘤中p16基因的研究进展.国外医学遗传学分册,1999,22(2)：64.
[25]陈辉,王文忠,丁劲松,等.粉防已碱诱导人肺腺癌细胞SPC-A-1凋亡的机制[J].实用医学杂志,2009,25(19)：3187～3189.
[26]韩晓兵,柳友清,卢运萍,等.粉防已碱对人卵巢癌细胞株A2780增殖与凋亡的影响[J].中国肿瘤临床,2006,33(4)：190～193.
[27]陈宝安,王为,林国为.汉防已甲素抗肿瘤作用的研究进展[J].南京中医药大学学报(自然科学版),2001,17(2)：128-130.
[28]余微波,谷俊朝.乳腺癌动物模型的建立[J].国外医学外科学分册,2005,32(1)：63～66.
[29]李文生,姜德咏,丁建光,等.吲哚美辛诱导视网膜色素上皮细胞凋亡的实验研究[J].中国临床康复,2004,8(20)：4126-4127.
[30]Conway EM, Pollefeyt S, Steiner-Mosonyi M, et al. Deficiency of surviving in transgenic mice exacerbates Fas induced apoptosis via mitochondria pathways [J]. Gastroenterology,2002,123 (2):619-631.
[31]Altieri DC. The molecular basis and potential role of surviving in cancer diagnosis and therapy [J].Trends Mol Med,2001,7(12):542-547.
[32]吴炅,沈镇宙.乳腺癌中Bcl-2基因族研究现状[J].中国癌症杂志,1998,8(3)：217～221.
[33]Li Y,Bhuiyan M,Mohammad RM,et al. Induction of apoptosis in breast cancer cells by TPA[J]. Oncogene,1998,17(22):2915-2920.
[34]Rosse T, Olivier R,Monnery L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c[J]. Nature,1998,391 (1):496-499.
[35]Ambrosini G,Adida C, Altieri DC. A novel anti-apoptosis gene survivin expressed in cancer and lymphoma[J]. Nature Med,1997,3(8):917-921.
[36]沙玉英,徐国光.Survivin和细胞周期蛋白Dl在乳腺癌中表达的临床意义[J].南通医学院学报,2004,24(3)269～270.
[37]Keitaro Tanaka, Shinji Iwamato,Goke Gon, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas [J]. Clinical Cancer Research,2000,1(6):127-134.
[38]Tamm I, Wang Y, Sausville E, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs [J]. CancerRes,1998,58:5315-5320.
[39]Shin S,Sung BJ,Cho YS,et al.An anti-apoptotic protein human Survivin is a direct inhibitor of caspase-3 and caspase-7 [J]. Biochemistry,2001,40:1117-1123.
[40]Takahashi Y,Kitadai Y, Bucana CD, et al.Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer[J].Cancer Res,1995, 55 (18):3964-3968.
[41]Salven P, Lymboussaki A, Heikkila P, et al.Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumors[J]. Am J Pathol,1998, 153 (1):103-108.
[42]邓俊芳.和厚朴酚抗胰腺癌作用及其机制的实验研究[D].浙江大学博士学位论文,2008：73.